10 results about "Autoantibody level" patented technology

The present disclosure relates to human antibodies specific to dermatomyositis antigen peptides, preparation methods and uses. Specifically, the present disclosure relates to a monoclonal antibody that specifically binds to MDA5 antigen protein, a preparation method of the monoclonal antibody and a use of the aforementioned monoclonal antibody in the preparation of a drug for the diagnosis, prevention or treatment of inflammatory myopathy or its complications. The antibody or antigen-binding fragment against MDA5 screened by the present disclosure specifically binds to MDA5 antigen, can be used as a reference standard for qualitative detection of MDA5 positivity, realizes qualitative or quantitative detection of the level of anti-MDA5 autoantibody in patients with inflammatory myopathy or its complications, and has important significance for the clinical diagnosis, disease monitoring and treatment of patients with DM, CAMD, DM-ILD, CADM-ILD and the like.

Methods of preparing therapeutic blood products from merged plasma donors are described. Therapeutic blood products include, for example, plasma, plasma proteins, and plasma fractions with improved safety by reducing the concentration of donor autoantibodies against Fc [epsilon] RI [beta] or eliminating such antibodies.

Provided herein are compounds, including compounds of any of the formulae described herein (e.g., Formula (I'), Formula (I), Formula (II)), and pharmaceutically acceptable salts thereof. Compounds provided herein are capable of covalently binding to and inhibiting neonatal fragment crystallizable receptor (FcRn) proteins and are therefore useful in the treatment and / or prevention of various diseases, including conditions associated with FcRn activity and / or immunoglobulin G (IgG) autoantibody levels in a subject.

A method for preparing therapeutic blood products from pooled plasma donors is provided. The therapeutic blood products include, for example, plasma, plasma proteins, and plasma fractions, in which safety is improved by reducing or eliminating the concentration of donor autoantibodies against FcεRIβ.

The invention relates to a humanized antibody of a dermatomyositis specific antigen as well as a preparation method and application of the humanized antibody. Amino acid sequences of HCDR1, HCDR2 and HCDR3 of a heavy chain of the antibody respectively comprise sequences as shown in SEQ ID No.6 to SEQ ID No.8, and amino acid sequences of LCDR1, LCDR2 and LCDR3 of a light chain of the antibody respectively comprise a sequence as shown in SEQ ID No.9, a sequence as shown in GQD and a sequence as shown in SEQ ID No.10. The anti-MDA5 human monoclonal antibody obtained through screening is high in activity, good in stability and high in MDA5 binding specificity, can serve as a reference standard for qualitative detection of MDA5 positive, can also be used for quantitative detection of the anti-MDA5 autoantibody level in patients suffering from inflammatory myopathy or complications of the inflammatory myopathy, and can be used for clinical application. And a new tool is provided for diagnosis, monitoring, treatment and the like of dermatomyositis and complications thereof.

Provided herein are cyclic peptides capable of binding to and inhibiting neonatal fragment crystallizable receptor (FcRn) proteins, and methods of using the same for the treatment and / or prevention of various diseases, including conditions associated with FcRn activity and / or immunoglobulin G (IgG) autoantibody levels in a subject.

Provided herein are cyclic peptides capable of covalently binding to and inhibiting neonatal fragment crystallizable receptor (FcRn) proteins, and methods of using the same for the treatment and / or prevention of various diseases, including conditions associated with FcRn activity and / or immunoglobulin G (IgG) autoantibody levels in a subject.

The present disclosure belongs to the field of biological medicine, and relates to a human antibody binding to a BP specific antigen peptide, a preparation method and use. Specifically, the present disclosure relates to a monoclonal antibody, wherein the antibody specifically binds to the NC16A domain of the BP180 antigen protein, a preparation method of the monoclonal antibody, and use of the aforementioned monoclonal antibody in preparation of a drug for diagnosis, prevention or treatment of bullous pemphigoid. The antibody or antigen binding fragment against BP180 screened by the present disclosure specifically binds to the BP180 antigen, can be used as a reference standard for qualitative detection of BP180 positivity, realizes quantitative detection of the level of the anti-BP180 NC16A autoantibody in BP patients, and has important significance for clinical diagnosis, disease monitoring and treatment of the BP patients.

Provided herein are cyclic peptides capable of binding to and inhibiting neonatal fragment crystallizable receptor (FcRn) proteins, and methods of using the same for the treatment and / or prevention of various diseases, including conditions associated with FcRn activity and / or immunoglobulin G (IgG) autoantibody levels in a subject.

Methods for treating systemic lupus erythematosus using compounds or pharmaceutical compositions that modulate the activity of Bcl-2 family proteins are disclosed. In some methods, the patient to be treated is diagnosed with lupus nephritis. In some methods, the compound or pharmaceutical composition is administered to the patient in need thereof at a therapeutically effective dose sufficient to elicit one or more effects selected from: reduced excretion of protein in the urine of the patient, reduced serum anti-dsDNA autoantibody levels in the patient, reduced skin lesion severity in the patient, reduced lymphadenopathy severity in the patient, reduced glomerulonephritis severity in the patient, reduced vasculitis severity in the patient, reduced lymphocyte cell counts in a peripheral blood mononuclear cell (PMBC) panel taken from the patient, reduced lymphocyte cell counts in the spleen of the patient, and reduced lymphocyte infiltration of the kidneys of the patient.